74.93

1.91% -1.46

After Hours: 74.93

Arrowhead Pharmaceuticals Inc (ARWR)

Overview News Price History Option Chain Financials Why ARWR Down? Discussions Forecast Stock Split

Arrowhead Pharmaceuticals Inc stock is traded at $74.93, with a volume of 1.26M. It is down -1.91% in the last 24 hours and up +22.78% over the past month. Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.

Previous Close:

$76.39

Open:

$77.25

24h Volume:

1.26M

Relative Volume:

0.50

Market Cap:

$10.49B

Revenue:

$1.09B

Net Income/Loss:

$233.57M

P/E Ratio:

48.71

EPS:

1.5382

Net Cash Flow:

$327.01M

1W Performance:

+6.84%

1M Performance:

+22.78%

6M Performance:

+85.88%

1Y Performance:

+435.98%

1-Day Range:

$73.61

$77.90

1-Week Range:

$68.97

$77.90

52-Week Range:

$12.44

$77.90

Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile

Name

Arrowhead Pharmaceuticals Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

626-696-4702

Address

177 E COLORADO BLVD, PASADENA, CA

Employee

711

Twitter

@ArrowheadPharma

Next Earnings Date

2026-05-07

Latest SEC Filings

ARWR's Discussions on Twitter

Compare ARWR vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ARWR Arrowhead Pharmaceuticals Inc	74.93	10.70B	1.09B	233.57M	327.01M	1.5382
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-21-26	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jun-05-24	Initiated	Goldman	Neutral
Dec-04-23	Initiated	BofA Securities	Buy
Sep-19-23	Initiated	Citigroup	Neutral
Jul-21-23	Initiated	TD Cowen	Outperform
May-12-23	Downgrade	SVB Securities	Outperform → Market Perform
Apr-26-23	Initiated	SMBC Nikko	Outperform
Apr-12-23	Upgrade	SVB Securities	Market Perform → Outperform
Mar-21-23	Initiated	Bernstein	Mkt Perform
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight
May-11-22	Upgrade	Robert W. Baird	Neutral → Outperform
Jan-19-22	Resumed	Goldman	Buy
Aug-06-21	Reiterated	Chardan Capital Markets	Buy
Jun-04-21	Resumed	Robert W. Baird	Neutral
Feb-05-21	Reiterated	H.C. Wainwright	Buy
Dec-21-20	Downgrade	Robert W. Baird	Outperform → Neutral
Dec-16-20	Initiated	UBS	Buy
Nov-19-20	Initiated	Citigroup	Buy
May-13-20	Initiated	RBC Capital Mkts	Outperform
May-08-20	Upgrade	Oppenheimer	Perform → Outperform
Apr-15-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Mar-24-20	Upgrade	SVB Leerink	Underperform → Mkt Perform
Mar-17-20	Initiated	Goldman	Neutral
Jan-21-20	Initiated	SVB Leerink	Underperform
Dec-13-19	Initiated	Oppenheimer	Perform
Nov-29-19	Reiterated	Chardan Capital Markets	Buy
Nov-27-19	Reiterated	B. Riley FBR	Buy
Nov-25-19	Upgrade	Robert W. Baird	Neutral → Outperform
Oct-24-19	Downgrade	Robert W. Baird	Outperform → Neutral
Oct-22-19	Reiterated	Chardan Capital Markets	Buy
Oct-03-19	Initiated	Robert W. Baird	Outperform
Sep-07-18	Upgrade	B. Riley FBR	Neutral → Buy
Sep-06-18	Reiterated	Chardan Capital Markets	Buy
Aug-08-18	Reiterated	Cantor Fitzgerald	Overweight
Jul-02-18	Reiterated	Chardan Capital Markets	Buy

View All

Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News

May 05, 2026

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals - Arrowhead Pharmaceuticals, Inc.

May 05, 2026

Madrigal expands MASH pipeline in potential $1B Arrowhead deal - BioWorld News

May 05, 2026

Madrigal outlays $1bn for Arrowhead’s siRNA MASH asset - Pharmaceutical Technology

May 05, 2026

Arrowhead Pharmaceuticals stock hits 52-week high at 77.23 USD - Investing.com

May 05, 2026

Madrigal picks up another siRNA asset for MASH, betting up to $1B with Arrowhead - BioSpace

May 05, 2026

Biotechnology company Arrowhead Pharmaceuticals announces a major collaboration agreement with Madrigal Pharmaceuticals. - Bitget

May 05, 2026

Arrowhead licenses MASH drug candidate to Madrigal for $1B By Investing.com - Investing.com Canada

May 05, 2026

After 46% liver fat cut, Madrigal licenses Arrowhead MASH drug - Stock Titan

May 05, 2026

JPMorgan Expects Arrowhead Pharma Stock to Rally on RNAi Portfolio Growth - TIKR.com

May 05, 2026

May 04, 2026

MSN Money - MSN

May 04, 2026

Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events - Business Wire

May 04, 2026

The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Australian Approval Of REDEMPLO For FCS - Yahoo Finance

May 04, 2026

Arrowhead upgraded at Morgan Stanley on upcoming catalysts - MSN

May 04, 2026

May 03, 2026

Is Arrowhead Pharmaceuticals (ARWR) Stock Price Out Of Line With Recent 1-Year Surge? - Sahm

May 03, 2026

Kornitzer Capital Management Inc. KS Makes New $2.38 Million Investment in Arrowhead Pharmaceuticals, Inc. $ARWR - MarketBeat

May 03, 2026

May 02, 2026

Arrowhead (ARWR) Rated Buy on Metabolic Pipeline Potential - Insider Monkey

May 02, 2026